头颈癌患者EORTC QLQ-C30量表评分的最小重要差异解读
该研究基于两项已发表的EORTC试验数据,回顾性估计头颈癌患者EORTC QLQ-C30量表评分随时间变化的组水平最小重要差异(MID)。锚定法MID可确定14个量表中有7个恶化MID和3个改善MID;组内变化绝对MID值为5至15分,组间变化为4至12分,多数MID在4至10分之间。
要点
- 头颈癌患者QLQ-C30组内变化MID绝对值为5至15分。
- 组间变化MID绝对值为4至12分,多数MID在4至10分。
- 14个量表中仅7个可确定恶化MID、3个可确定改善MID。
核心结论
- 若经验证,本研究的MID可辅助解读头颈癌患者特定QLQ-C30量表评分随时间的变化,并用于未来临床试验的样本量计算。
研究设计与样本
- 回顾性分析两项已发表的EORTC试验数据,以相关系数和临床合理性选择临床锚定。
- 采用均值变化法估计组内变化MID,采用线性回归估计组间变化MID,并考察分布法MID。
主要发现
- 锚定法MID可确定14个QLQ-C30量表中7个的恶化MID和3个的改善MID。
- 组内变化绝对MID值为5至15分,组间变化绝对MID值为4至12分。
- 多数MID在4至10分之间,MID随量表、变化方向和锚定不同而变化。
- 呼吸困难与恶心呕吐量表的MID因与锚定相关性低而更不确定。
关键数值与推荐
- 组内变化绝对MID值为5至15分,组间变化绝对MID值为4至12分。
- 多数MID在4至10分之间。
- 锚定法MID可确定7个量表的恶化MID和3个量表的改善MID。
临床怎么用
- 解读头颈癌患者QLQ-C30量表评分随时间变化时,可参考本研究估计的MID值。
- 设计头颈癌临床试验时,可利用MID信息辅助样本量计算。
- 对呼吸困难与恶心呕吐量表,因MID不确定性较高,解读时应谨慎。
局限性
- 数据为回顾性来源,结论需进一步验证。
- 呼吸困难与恶心呕吐量表的MID因与锚定相关性低而更不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to estimate minimally important difference (MID) for interpreting group-level change over time for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) scores in head and neck cancer. METHODS: Data were derived retrospectively from two published EORTC trials. Clinical anchors were selected using correlation strength and clinical plausibility of the given anchor/QLQ-C30 scale pair. MIDs for within-group and between-group change were estimated via the mean change method and linear regression, respectively. Distribution-based MIDs were also examined. MIDs for two of the scales, dyspnea and nausea/vomiting, are more uncertain considering their low correlations with the anchors. RESULTS: Anchor-based MIDs could be determined for deterioration in 7 of the 14 QLQ-C30 scales assessed, and in 3 scales for improvement. MIDs varied by scale, direction of change, and anchor. Absolute MID values ranged from 5 to 15 points for within-group change and 4 to 12 for between-group change. Most MIDs were within 4 to 10 points. CONCLUSIONS: Our findings, if confirmed, will aid interpreting changes in selected QLQ-C30 scale scores over time and inform sample size calculations in future clinical trials in head and neck cancer.
引用
- Musoro JZ, Coens C, Singer S, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. Head Neck. 2020. PMID: 32627261. doi:10.1002/hed.26363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。